The CEO of ASLAN Pharmaceuticals, Dr. Carl Firth discusses the implications surrounding the company’s imminent initial public offering on Taiwan’s stock exchange, while explaining how this move serves to position ASLAN as Singapore’s first local success story.
Having just completed a pre-IPO financing round, it seems the company has many exciting milestones in the pipeline. How will these newly acquired funds be allocated?
"There are no true biotechs listed in Singapore today, and that just really comes down the level of risk that investors are willing to take."
